Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Gross Profit of $169.75 million for the year ending 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +0.9% in Gross Profit from 2024 to 2025.
- This data is from TREACE MEDICAL CONCEPTS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $8.87 million | Q2 2020: $5.65 million | Q3 2020: $11.36 million | Q1 2021: $15.38 million | Q2 2021: $16.71 million | Q3 2021: $17.37 million | Q1 2022: $23.92 million | Q2 2022: $24.68 million | Q3 2022: $26.97 million | Q1 2023: $34.16 million | Q2 2023: $34.28 million | Q3 2023: $32.76 million | Q1 2024: $40.98 million | Q2 2024: $35.67 million | Q3 2024: $36.13 million | Q1 2025: $41.89 million | Q2 2025: $37.75 million | Q3 2025: $39.71 million.
- Over the full 7 years of available data (2019 to 2025), TREACE MEDICAL CONCEPTS, INC.'s Gross Profit has grown by 434.1%.
- Historical annual values: Fiscal year 2025: $169.75 million | Fiscal year 2024: $168.26 million | Fiscal year 2023: $151.94 million | Fiscal year 2022: $116.31 million | Fiscal year 2021: $77.53 million | Fiscal year 2020: $44.90 million | Fiscal year 2019: $31.79 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: